Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Retained Earnings (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Retained Earnings for 14 consecutive years, with -$1.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 1.05% year-over-year to -$1.9 billion, compared with a TTM value of -$1.9 billion through Dec 2025, down 1.05%, and an annual FY2025 reading of -$1.9 billion, down 1.05% over the prior year.
  • Retained Earnings was -$1.9 billion for Q4 2025 at Heron Therapeutics, roughly flat from -$1.9 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $40000.0 in Q3 2024 and bottomed at -$1.9 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$1.3 billion, with a median of -$1.8 billion recorded in 2022.
  • The sharpest move saw Retained Earnings plummeted 44389550.0% in 2022, then skyrocketed 4100.0% in 2024.
  • Year by year, Retained Earnings stood at -$6000.0 in 2021, then crashed by 29924150.0% to -$1.8 billion in 2022, then decreased by 6.16% to -$1.9 billion in 2023, then fell by 0.71% to -$1.9 billion in 2024, then decreased by 1.05% to -$1.9 billion in 2025.
  • Business Quant data shows Retained Earnings for HRTX at -$1.9 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.9 billion in Q2 2025.